Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $381.61 in the prior trading day, HCA Healthcare Inc (NYSE: HCA) closed at $382.91%, Up $0.34%. In other words, the price has increased by $0.34 from its previous closing price. On the day, 0.99 million shares were traded. HCA stock price reached its highest trading level at $384.76 during the session, while it also had its lowest trading level at $378.54.
Ratios:
Our goal is to gain a better understanding of HCA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 86.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.29. For the most recent quarter (mrq), Quick Ratio is recorded 0.86 and its Current Ratio is at 0.98.
On July 16, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $394.
Wells Fargo Upgraded its Underweight to Equal Weight on May 29, 2025, while the target price for the stock was maintained at $385.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 13 ’25 when Foster Jon M sold 15,698 shares for $369.32 per share. The transaction valued at 5,797,661 led to the insider holds 12,646 shares of the business.
Foster Jon M bought 15,698 shares of HCA for $5,797,660 on May 13 ’25. On Feb 14 ’25, another insider, Berres Jennifer, who serves as the SVP & Chief Human Res. Officer of the company, sold 9,533 shares for $322.59 each. As a result, the insider received 3,075,240 and left with 15,412 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCA now has a Market Capitalization of 89598640128 and an Enterprise Value of 138078453760. As of this moment, HCA’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.08, and their Forward P/E ratio for the next fiscal year is 13.56. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.23. Its current Enterprise Value per Revenue stands at 1.899 whereas that against EBITDA is 9.523.
Stock Price History:
The Beta on a monthly basis for HCA is 1.41, which has changed by 0.03809035 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, HCA has reached a high of $417.14, while it has fallen to a 52-week low of $289.98. The 50-Day Moving Average of the stock is 3.44%, while the 200-Day Moving Average is calculated to be 11.57%.
Shares Statistics:
The stock has traded on average 1.50M shares per day over the past 3-months and 1355580 shares per day over the last 10 days, according to various share statistics. A total of 236.14M shares are outstanding, with a floating share count of 166.30M. Insiders hold about 28.93% of the company’s shares, while institutions hold 66.59% stake in the company. Shares short for HCA as of 1752537600 were 3888909 with a Short Ratio of 2.59, compared to 1749772800 on 4638449. Therefore, it implies a Short% of Shares Outstanding of 3888909 and a Short% of Float of 2.29.
Dividends & Splits
In the trailing 12 months, HCA’s forward annual dividend rate was 2.76, compared to 2.76 this year. Against a Trailing Annual Dividend Yield of 0.007232515The stock’s 5-year Average Dividend Yield is 0.76.
Earnings Estimates
HCA Healthcare Inc (HCA) is presently subject to a detailed evaluation by 17.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $7.36, with high estimates of $7.75 and low estimates of $6.87.
Analysts are recommending an EPS of between $26.89 and $25.51 for the fiscal current year, implying an average EPS of $26.25. EPS for the following year is $28.26, with 23.0 analysts recommending between $29.54 and $25.34.
Revenue Estimates
19 analysts predict $18.55B in revenue for the current quarter. It ranges from a high estimate of $18.85B to a low estimate of $18.36B. As of the current estimate, HCA Healthcare Inc’s year-ago sales were $17.49BFor the next quarter, 19 analysts are estimating revenue of $19.5B. There is a high estimate of $20.1B for the next quarter, whereas the lowest estimate is $19.2B.
A total of 23 analysts have provided revenue estimates for HCA’s current fiscal year. The highest revenue estimate was $75.77B, while the lowest revenue estimate was $74.24B, resulting in an average revenue estimate of $74.99B. In the same quarter a year ago, actual revenue was $70.6BBased on 22 analysts’ estimates, the company’s revenue will be $78.44B in the next fiscal year. The high estimate is $80.81B and the low estimate is $76.41B.
